These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 33758900)
21. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India. Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA Front Public Health; 2022; 10():967447. PubMed ID: 36276377 [TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients. Makatsa MS; Tincho MB; Wendoh JM; Ismail SD; Nesamari R; Pera F; de Beer S; David A; Jugwanth S; Gededzha MP; Mampeule N; Sanne I; Stevens W; Scott L; Blackburn J; Mayne ES; Keeton RS; Burgers WA Front Plant Sci; 2021; 12():589940. PubMed ID: 33868324 [No Abstract] [Full Text] [Related]
23. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population. Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691 [TBL] [Abstract][Full Text] [Related]
25. Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform. Chaudhury S; Hutter J; Bolton JS; Hakre S; Mose E; Wooten A; O'Connell W; Hudak J; Krebs SJ; Darden JM; Regules JA; Murray CK; Modjarrad K; Scott P; Peel S; Bergmann-Leitner ES PLoS One; 2021; 16(6):e0252628. PubMed ID: 34081747 [TBL] [Abstract][Full Text] [Related]
26. Methodological approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation with serologic and neutralizing antibody responses. Pisanic N; Antar AAR; Kruczynski KL; Gregory Rivera M; Dhakal S; Spicer K; Randad PR; Pekosz A; Klein SL; Betenbaugh MJ; Detrick B; Clarke W; Thomas DL; Manabe YC; Heaney CD J Immunol Methods; 2023 Mar; 514():113440. PubMed ID: 36773929 [TBL] [Abstract][Full Text] [Related]
27. Fcγ-Receptor-Based Enzyme-Linked Immunosorbent Assays for Sensitive, Specific, and Persistent Detection of Anti-SARS-CoV-2 Nucleocapsid Protein IgG Antibodies in Human Sera. Deschermeier C; Ehmen C; von Possel R; Murawski C; Rushton B; Amuasi J; Sarpong N; Maiga-Ascofaré O; Rakotozandrindrainy R; Asogun D; Ighodalo Y; Oestereich L; Duraffour S; Pahlmann M; Emmerich P J Clin Microbiol; 2022 Jun; 60(6):e0007522. PubMed ID: 35574677 [TBL] [Abstract][Full Text] [Related]
28. Validation of laboratory developed serology assays for detection of IgG antibody to severe acute respiratory syndrome coronavirus 2 in the South African population. Matefo L; Cloete VV; Armand BP; Dominique G; Samantha P; John F; Craig T; Daniel W; Theresa L; Sunetra G; Maréza B; Danelle VJ; Jane BF J Virol Methods; 2022 Sep; 307():114571. PubMed ID: 35750222 [TBL] [Abstract][Full Text] [Related]
29. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Rosado J; Pelleau S; Cockram C; Merkling SH; Nekkab N; Demeret C; Meola A; Kerneis S; Terrier B; Fafi-Kremer S; de Seze J; Bruel T; Dejardin F; Petres S; Longley R; Fontanet A; Backovic M; Mueller I; White MT Lancet Microbe; 2021 Feb; 2(2):e60-e69. PubMed ID: 33521709 [TBL] [Abstract][Full Text] [Related]
30. Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study. Snyder T; Ravenhurst J; Cramer EY; Reich NG; Balzer LB; Alfandari D; Lover AA medRxiv; 2021 May; ():. PubMed ID: 33758898 [TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 antibody seroprevalence after the first wave among workers at a community healthcare system in the Greater Boston area. Bruno-Murtha LA; Osgood R; Lan FY; Buley J; Nathan N; Weiss M; MacDonald M; Kales SN; Sayah AJ Pathog Glob Health; 2021 Jul; 115(5):331-334. PubMed ID: 33729103 [TBL] [Abstract][Full Text] [Related]
32. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461 [TBL] [Abstract][Full Text] [Related]
33. Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy. Polvere I; Parrella A; Casamassa G; D'Andrea S; Tizzano A; Cardinale G; Voccola S; Porcaro P; Stilo R; Vito P; Zotti T Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33803299 [TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia. Janha RE; Bah A; Jah H; Touray F; Idris Y; Keita S; Gaye Y; Jallow S; Faye-Joof T; Njie B; Craik R; Mohammed NI; von Dadelszen P; D'Alessandro U; Roca A; Int J Infect Dis; 2023 Oct; 135():109-117. PubMed ID: 37586660 [TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189 [TBL] [Abstract][Full Text] [Related]
36. Dynamics of SARS-CoV-2 exposure in Malawian infants between February 2020 and May 2021. Baroncelli S; Galluzzo CM; Orlando S; Mphwere R; Kavalo T; Luhanga R; Amici R; Floridia M; Andreotti M; Scarcella P; Marazzi MC; Giuliano M J Clin Virol Plus; 2022 Nov; 2(4):100110. PubMed ID: 36128323 [TBL] [Abstract][Full Text] [Related]
37. Riding high: seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020-February 2022. Duong S; Burtniak J; Gretchen A; Mai A; Klassen P; Wei Y; Loeppky C; Shaw SY; Bullard J; Van Caeseele P; Stein DR BMC Public Health; 2023 Dec; 23(1):2420. PubMed ID: 38053033 [TBL] [Abstract][Full Text] [Related]
38. Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study. Gebrecherkos T; Kiros YK; Challa F; Abdella S; Gebreegzabher A; Leta D; Desta A; Hailu A; Tasew G; Abdulkader M; Tessema M; Tollera G; Kifle T; Arefaine ZG; Schallig HH; Adams ER; Urban BC; de Wit TFR; Wolday D PLoS One; 2022; 17(3):e0263627. PubMed ID: 35320286 [TBL] [Abstract][Full Text] [Related]
39. Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in Pakistan. Masood KI; Qaiser S; Abidi SH; Khan E; Mahmood SF; Hussain A; Ghous Z; Imtiaz K; Ali N; Hasan M; Memon HA; Yameen M; Ali S; Baloch S; Lakhani G; Alves PM; Iqbal NT; Ahmed K; Iqbal J; Bhutta ZA; Hussain R; Rottenberg M; Simas JP; Veldhoen M; Ghias K; Hasan Z BMC Infect Dis; 2023 Dec; 23(1):846. PubMed ID: 38041026 [TBL] [Abstract][Full Text] [Related]